Affiliation:
1. St John's Institute of Dermatology Guy's and St Thomas’ NHS Foundation Trust London UK
2. King's College London London UK
Abstract
AbstractBackgroundInclusive, generalisable research is vital to inform evidence‐based patient care. However, people from ethnic minority backgrounds remain underrepresented in research, increasing health disparities in under‐served communities.ObjectivesCodevelop a toolkit to increase the representation of people from ethnic minority groups in skin research.MethodsOur four‐phase approach comprised: (1) focus group discussions with individuals from ethnic minority groups with skin diseases to identify barriers and enablers to participate in skin research, (2) a narrative literature review, (3) development of a skin research inclusion toolkit, (4) dissemination of findings.ResultsFocus group discussions (phase 1) identified a positive value model (belief in the value of research) and inclusive recruitment strategies (e.g. strong patient–recruiter relationships) as enablers to participation. Barriers included mistrust in research (e.g. poor information on personal data use) and social stigma of skin disease. Our narrative literature review (phase 2) reinforced these themes. Social stigma may accentuate feelings of shame or embarrassment associated with a skin condition. Mistrust is accentuated by a lack of information or understanding about research processes. Understanding distinct motivators for research participation across ethnic groups may help to cultivate a positive value model. Inclusive recruitment strategies should be codeveloped with populations of interest and culturally competent research teams to build lasting partnerships.Phases 1‐2 informed a skin research inclusion toolkit (phase 3), which recommends researchers formulate (i) an inclusion plan during study design (e.g. consider differences in pathophysiology of skin diseases across ethnic groups), (ii) inclusive enrolment strategies (e.g. skin‐of‐colour education to clinicians and patients to address disease‐associated stigma, codevelop study materials including translations) and (iii) retention strategies (e.g. time or travel reimbursement, timely feedback of findings). In phase 4, findings were disseminated to focus group participants.ConclusionsOur co‐designed toolkit has the potential to improve ethnic diversity in skin research cohorts to enable more representative findings.
Reference30 articles.
1. Ethnic inequalities in limiting health and self‐reported health in later life revisited;Evandrou M;J Epidemiol Community Health,2016
2. Ethnic differences in SARS‐CoV‐2 infection and COVID‐19‐related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform;Mathur R;The Lancet,2021
3. Racial and ethnic underrepresentation in dermatology clinical trials;Mineroff J;J Am Acad Dermatol,2023
4. U.S. Food and Drug Administration.Collection of race and ethnicity data inclinical trials.2016[cited 2023 Oct 18]. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials
5. U.S. Food and Drug Administration.Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations inclinical trials.2022[cited 2023 Oct 18]. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations